Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4.

PloS one - 1 Jan 2016

Rizk Hanan H, Hamdy Nadia M, Al-Ansari Nadia L, El-Mesallamy Hala O

Abstract excerpt

BACKGROUND: Egypt has the highest prevalence of a difficult to treat chronic hepatitis C virus (HCV), genotype 4. Pretreatment factors could guide individualization of therapy which aids in treatment optimization and interleukin IL28B gene polymorphism has been shown to closely relate to HCV treatment response. Polymorphisms in genes encoding inhibitors of T-cell response, which have role in disease progression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CTLA-4 Antigen
Share to Interferon-alpha
Share to Interferons

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukins

Share to Polyethylene Glycols

Share to Programmed Cell Death 1 Receptor

Share to Ribavirin

Share to ROC Curve

Source

Open in PubMed Open full text

Identifiers

PMID: 27100663
DOI: 10.1371/journal.pone.0153895
PMCID: PMC4839712

Genes

AFP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4.PMID 27100663Read ↗

Interferon-γ inducible protein-10 and interleukin 28B gene polymorphism as predictive markers for genotype 4 hepatitis C virus treatment response.Semantic proximity Read ↗

IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.Semantic proximity Read ↗

Interleukin 28B polymorphisms and therapy response in Egyptian hepatitis C genotype-4 patients.Semantic proximity Read ↗

Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4Semantic proximity Read ↗

The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients.Semantic proximity Read ↗

IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infectionSemantic proximity Read ↗

IL-28B polymorphisms correlated with treatment response in HCV-4 mono-infected patients: a meta-analysis.Semantic proximity Read ↗

Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C.Semantic proximity Read ↗

Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.Semantic proximity Read ↗

Is rs8099917 polymorphism of IL-28B gene a good predictor of response to therapy of HCV than rs12979860? An Egyptian study.Semantic proximity Read ↗

Interleukin 28B Polymorphism Predicts Treatment Outcome Among Egyptian Patients Infected With HCV Genotype 4.Semantic proximity Read ↗

Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.